Product sales grew by 3% at CER to $3.64bn, boosted by rare diseases (+6%) but pulled down by the neuroscience business (-4%). A CER growth of 3% in the US and 4% in the international markets was further complemented by a forex tailwind of 4ppts, resulting in reported product sales growth of 7%. All revenue numbers in CER unless specified otherwise. Royalty income declined by 20% to $129m, primarily due to the reclassification of Adderall XR in product sales. Total sales, in effect, increased
04 Jul 2018
Healthy numbers in Q1, despite disappointing Lialda and Cinryze
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy numbers in Q1, despite disappointing Lialda and Cinryze
Shires Income PLC GBP (SHRS:LON) | 226 5.6 1.1% | Mkt Cap: 93.3m
- Published:
04 Jul 2018 -
Author:
Kamla Singh -
Pages:
3
Product sales grew by 3% at CER to $3.64bn, boosted by rare diseases (+6%) but pulled down by the neuroscience business (-4%). A CER growth of 3% in the US and 4% in the international markets was further complemented by a forex tailwind of 4ppts, resulting in reported product sales growth of 7%. All revenue numbers in CER unless specified otherwise. Royalty income declined by 20% to $129m, primarily due to the reclassification of Adderall XR in product sales. Total sales, in effect, increased